Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (1038)	7/25/1997 10:06:00 AM
From: Biomaven	of 6136

John, You wrote: "Peter, these critics and yourself need to study more about antiretroviral therapy. Viracept's diarrhea has been completely overblown, and is only important for citics of the company's stock price. " Hey - I was just reporting the WSJ article that mentioned Agouron, for the benefit of those that may not have seen it. On what basis do you accuse me of "needing to study more about antiretroviral therapy?" I neither supported or endorsed the report myself. If you look at my posts you will see I've never been critical of Viracept, (indeed I posted that I thought it was the clear first choice for new patients) and I've never been short the stock. (I'm a long-time shareholder, but sold at 90 and back in again around 80). My only disagreement with you is on what PE the stock will support, because I think David S. has a valid point (his only one!) in that the market will feel Viracept has a shorter "half-life" than the average drug. I appreciate your informative posts, but please calm down! Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next